General
Preferred name
cerivastatin
Synonyms
CERIVASTATIN SODIUM ()
Cerivastatin (sodium) ()
Cerivastatin (sodium salt) ()
Cerivastatin sodium salt ()
BAY-W-6228 ()
Baycol ()
BAY W 6228 ()
Lipobay ()
Cerivastatina ()
Cerivastatine ()
rel-Cerivastatin ()
P&D ID
PD009115
CAS
143201-11-0
145599-86-6
2771241-29-1
Tags
available
drug
Approved by
FDA
First approval
1997
Drug indication
Cardiovascular disease
Hyperlipidaemia
Multiple myeloma
Drug Status
approved
withdrawn
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect[1][2].
PRICE 239
DESCRIPTION Cerivastatin sodium (BAY W 6228 sodium) is an orally active and highly potent HMG-CoA reductase inhibitor with lipid-lowering activity that can reduce low-density lipoprotein cholesterol levels. Cerivastatin sodium has anticancer effects and can be used to study primary hyperlipidemia.
DESCRIPTION Cerivastatin is a cholesterol-lowering drug. (GtoPdb)
PRICE 1361
DESCRIPTION Cerivastatin is an orally active and highly effective HMG-CoA reductase inhibitor with anticancer and lipid-lowering effects. Cerivastatin can reduce low-density lipoprotein cholesterol levels, inhibit the proliferation and invasion of MDA-MB-231 cells, and can be used to study primary hyperlipidemia. (TargetMol Bioactive Compound Library)
DESCRIPTION Cerivastatin, a competitive HMG-CoA reductase inhibitor effective in lowering LDL cholesterol and triglycerides, is used to treat primary hypercholesterolemia and mixed dyslipidemia. (Enamine Bioactive Compounds)
Cell lines
6
Organisms
0
Compound Sets
24
Cayman Chemical Bioactives
20362
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1200563
CHEMBL1477
ChEMBL Drugs
CHEMBL1200563
CHEMBL1477
Concise Guide to Pharmacology 2017/18
2950
Concise Guide to Pharmacology 2019/20
2950
Concise Guide to Pharmacology 2021/22
2950
Concise Guide to Pharmacology 2023/24
2950
CZ-OPENSCREEN Bioactive Library
DrugBank
DB00439
DrugBank Approved Drugs
DB00439
DrugCentral
577
DrugCentral Approved Drugs
577
DrugMAP
DMXCM7H
DrugMAP Approved Drugs
DMXCM7H
Enamine Bioactive Compounds
EBC-254047
Guide to Pharmacology
2950
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1477
MedChem Express Bioactive Compound Library
HY-109523
NIH Clinical Collections (NCC)
NPC Screening Collection
ReFrame library
TargetMol Bioactive Compound Library
T14931
Withdrawn 2.0
w129
External IDs
58
Properties
(calculated by RDKit )
Molecular Weight
459.24
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
11
Ring Count
2
Aromatic Ring Count
2
cLogP
4.88
TPSA
99.88
Fraction CSP3
0.46
Chiral centers
2.0
Largest ring
6.0
QED
0.44
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
hydroxymethylglutaryl coenzyme A reductase inhibitor
Target
HMG-CoA Reductase
HMG-CoA Reductase (HMGCR)
Ferroptosis
ATC
C10AA06
Toxicity type
muscular
Pathway
Apoptosis
Metabolism
Metabolic Enzyme/Protease
Source data